TransMedics Group, Inc. (TMDX) Guidance & Earnings Results
On 2026-08-04 TransMedics Group, Inc. raised guidance: "Full-year 2026 revenue guidance raised to $737M-$757M from…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TMDXTransMedics Group, Inc.Follow TMDX — free
—
Price chart with a free account
- Market cap
- 2.5B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 4 Aug 26 | Raised | Full-year 2026 revenue guidance raised to $737M-$757M from $727M-$757M · full year |
| 5 May 26 | Reaffirmed | Full year 2026 revenue guidance $727M-$757M (20-25% growth) · full year |
| 24 Feb 26 | Raised | FY2026 revenue guidance $727M-$757M, 20-25% growth · full year |
| 29 Oct 25 | Raised | FY2025 revenue guidance raised to $595-605M (from $585-605M); midpoint represents 36% growth · full year |
| 30 Jul 25 | Raised | FY2025 revenue raised to $585-605M from $565-585M; midpoint $595M represents 35% YoY growth · full year |
TransMedics Group, Inc. — questions
- What guidance did TransMedics Group, Inc. give?
- On 2026-08-04: "Full-year 2026 revenue guidance raised to $737M-$757M from $727M-$757M"
- When does TransMedics Group, Inc. report earnings?
- TransMedics Group, Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from TransMedics Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.